GH Research PLC GHRS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 4:00 PM EDT
12.73quote price arrow down-0.01 (-0.08%)
Volume
29,963
52 week range
5.05 - 14.64
Loading...
  • Open12.90
  • Day High12.91
  • Day Low12.60
  • Prev Close12.74
  • 52 Week High14.64
  • 52 Week High Date07/31/23
  • 52 Week Low5.05
  • 52 Week Low Date12/18/23

Key Stats

  • Market Cap662.318M
  • Shares Out52.03M
  • 10 Day Average Volume0.06M
  • Dividend-
  • Dividend Yield-
  • Beta0.8
  • YTD % Change119.48

KEY STATS

  • Open12.90
  • Day High12.91
  • Day Low12.60
  • Prev Close12.74
  • 52 Week High14.64
  • 52 Week High Date07/31/23
  • 52 Week Low5.05
  • 52 Week Low Date12/18/23
  • Market Cap662.318M
  • Shares Out52.03M
  • 10 Day Average Volume0.06M
  • Dividend-
  • Dividend Yield-
  • Beta0.8
  • YTD % Change119.48

RATIOS/PROFITABILITY

  • EPS (TTM)-0.68
  • P/E (TTM)-18.61
  • Fwd P/E (NTM)-14.10
  • EBITDA (TTM)-40.907M
  • ROE (TTM)-15.18%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)0.44%

EVENTS

  • Earnings Date09/02/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On GH Research PLC

 

Profile

MORE
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach....
Florian Schonharting
Non-Executive Chairman of the Board
Theis Terwey
Chief Executive Officer
Julie Ryan
Vice President - Finance
Address
Joshua Dawson House, Dawson Street
Dublin
D02 RY95
Ireland

Top Peers

SYMBOLLASTCHG%CHG
MLYS
Mineralys Therapeutics Inc
13.15+0.08+0.61%
PRME
Prime Medicine Inc
7.04+0.28+4.14%
HLVX
Hillevax Inc
15.57+0.47+3.11%
SVRA
Savara Inc
4.72-0.11-2.28%
LXRX
Lexicon Pharmaceuticals Inc
1.84-0.10-5.15%